Expenses outpaced revenue, squeezing Innova Captab's Q2 margin
Revenue grew +5.41% qoq, but operating margin narrowed 1.44 percentage points as expenses rose +7.20%.
Filed 13 Nov 2026, 17:51 IST · after market close · Innova Captab Ltd (INNOVACAP)
Key takeaways
- Consolidated revenue grew +5.41% qoq, but expenses rose +7.20%, pulling net profit down -3.87%.
- Operating margin narrowed 1.44 percentage points qoq to 14.09% as costs grew faster than revenue.
- Innova Captab's operating margin was 7.55 percentage points below the 21.64% Healthcare peer median across 103 reported companies.
Price around the results
Revenue momentum did not convert into profit growth
On a consolidated basis, revenue increased +5.41% qoq, but operating profit fell -4.35% and net profit declined -3.87%. The gap reflects expenses growing +7.20%, faster than revenue, which reduced operating leverage in Q2FY27.
Lower tax and interest costs only partly cushioned the margin squeeze
Operating margin fell 1.44 percentage points qoq because costs outpaced revenue growth. Interest expense declined -3.61%, while the tax rate fell 0.54 percentage points, partly limiting the decline in net profit. Other income contributed 4.37% of pre-tax profit, so it was not a major driver of reported earnings.
Margin reversed after improving in Q1FY27
Operating margin rose from 14.54% in Q4FY26 to 15.53% in Q1FY27, before falling to 14.09% in Q2FY27. The latest margin was 7.55 percentage points below the 21.64% median for 103 Healthcare peers that had reported the quarter, placing the company 23rd from the bottom.
Management points to CDMO, branded generics and capacity
Management said CDMO and Branded Generics saw business momentum in Q2FY27, while its stated priorities include strengthening CDMO, expanding branded generics and ramping up manufacturing capacity. The company also said it remains focused on operational excellence, manufacturing efficiency and quality. Management flagged that higher inventory related to the Jammu plant affected net working capital.
Results were filed after market close
The consolidated results were filed after market close on 13 Nov 2026. The stock's immediate response is therefore not covered in this update.
Q2FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q2FY27 | Q1FY27 | QoQ |
|---|---|---|---|
| Revenue | ₹496 cr | ₹471 cr | +5.41% |
| Other income | ₹2 cr | ₹2 cr | +22.39% |
| Expenses | ₹426 cr | ₹398 cr | +7.20% |
| Operating profit | ₹70 cr | ₹73 cr | -4.35% |
| Operating margin (%) | 14.09% | 15.53% | — |
| Interest | ₹4 cr | ₹4 cr | -3.61% |
| Depreciation | ₹12 cr | ₹12 cr | +1.11% |
| Profit before tax | ₹56 cr | ₹59 cr | -4.54% |
| Tax | ₹14 cr | ₹15 cr | -6.59% |
| Net profit | ₹42 cr | ₹44 cr | -3.87% |
| EPS (₹) | ₹7.41 | ₹7.71 | -3.89% |
Operating margin of 14.09% compares with a Healthcare sector median of 21.64% across 103 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- CDMO and Branded Generics businesses recorded healthy business momentum in Q2 FY27.
Guidance & outlook
- The company plans to strengthen its CDMO positioning, expand branded generics and ramp up manufacturing capacities.
- The company is focused on sustaining long-term growth through disciplined capital allocation decisions.
New initiatives
- The company is focusing on operational excellence, manufacturing efficiency and quality.
Problems & risks
- Net working capital was affected by increased inventory related to the Jammu plant.
What to watch
- Whether operating margin recovers from 14.09% after the 1.44 percentage-point qoq decline.
- Whether expense growth moderates from +7.20% qoq relative to revenue growth of +5.41%.
- Whether other income remains near 4.37% of pre-tax profit without becoming a larger earnings driver.